Picture of Bruker logo

BRKR — Bruker News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Scientific instruments maker Bruker beats Q3 estimates, cuts FY guidance on weak demand

Overview

Bruker Q3 2025 revenue of $860.5 mln beats analyst expectations despite a 0.5% yoy decline

Adjusted EPS for Q3 2025 beats consensus at $0.45, despite a decline from last year

Company lowers FY2025 guidance, citing weaker demand and EPS dilution from higher share count

Outlook

Bruker expects FY2025 revenue of $3.41 to $3.44 bln, with 1-2% growth yoy

Company forecasts FY2025 non-GAAP EPS of $1.85 to $1.90

Bruker anticipates significant margin expansion and EPS growth in FY2026

Result Drivers

BOOKINGS GROWTH - Mid-single digit percentage organic bookings growth driven by academic/government and biopharma markets

PRODUCT RECEPTION - New spatial biology and proteomics solutions well-received by biopharma and academic customers

DEMAND WEAKNESS - Revenue decline due to weaker academic and research instruments demand in H1 2025

Key Details

MetricBeat/MissActualConsensus Estimate
Q3 RevenueBeat$860.50 mln$848.72 mln (12 Analysts)
Q3 Adjusted EPSBeat$0.45$0.33 (13 Analysts)
Q3 Net Income-$58.50 mln
Q3 Gross Profit$379.40 mln
Q3 Operating Expenses$431.20 mln
Q3 Operating Income-$51.80 mln
Press Release: ID:nBw43qLnva For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Bruker

See all news